We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Arecor Therapeutics plc (AREC) ORD GBP0.01

Sell:127.00p Buy:130.00p 0 Change: 1.50p (1.17%)
Market closed |  Prices as at close on 19 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:127.00p
Buy:130.00p
Change: 1.50p (1.17%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 19 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:127.00p
Buy:130.00p
Change: 1.50p (1.17%)
Market closed |  Prices as at close on 19 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Arecor Therapeutics plc is a United Kingdom-based globally focused biopharmaceutical company. The Company, by applying its technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver therapeutic products. Its portfolio includes AT247 - Ultra-Rapid Acting Insulin and AT278 - Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. The Company's AT278 is an ultra-concentrated novel formulation of ultra-rapid acting insulin. Its subsidiary, Tetris Pharma Ltd, has a portfolio of injectable products including Ogluo, which is a ready-to-use glucagon for emergency use to treat hypoglycemia.

Contact details

Address:
Chesterford Research Park
Little Chesterford
SAFFRON WALDEN
CB10 1XL
United Kingdom
Telephone:
+44 (01223) 426060
Website:
https://arecor.com/

Important dates

Future events
There are no future events available.
Past events
Trading Announcement 01 February 2024 01/02/24
Interim results 14 September 2023 14/09/23
AGM 09 June 2023 09/06/23
Annual report 04 May 2023 04/05/23
Final results 20 April 2023 20/04/23

General stock information

EPIC:
AREC
ISIN:
GB00BMWLM973
Market cap:
£39.82 million
Shares in issue:
30.63 million
Sector:
No specific Industry
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Sarah Howell
    Chief Executive Officer, Executive Director
  • Susan Lowther
    Chief Financial Officer, Executive Director, Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.